- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00361114
IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria.
Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Uncomplicated Malaria and in 2-10 Month Old Asymptomatic Infants.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Introduction and Rational
This is part of a multicentre trial looking into antimalarial resistance within a series of Intermittent Preventive Treatment of malaria in Infants (IPTi) studies. IPTi is a promising intervention to reduce malaria in infants in malaria endemic countries. 3 doses of antimalarial drugs are given in the first year of life to asymptomatic infants at the time of 2nd and 3rd Diptheria, Tetanus and Pertusus immunisation and again at 9 months of age at time of measles immunisation. In the current Kilimanjaro IPTi study we are comparing 3 antimalarials (Mefloquine MQ, sulfadoxine/pyremethamine SP and chlorproguanil/dapsone CD) against placebo for IPTi in 2 transmission zones. Two published studies using SP for IPTi have shown different efficacies for this intervention. The first study (Schellenberg et al 2001) showed a 62% reduction in clinical cases of malaria and the second (Chandramohan et al, 2005) showed only a 25% reduction in clinical cases of malaria. The two sites differ in several ways, the first was carried out in an area of moderate to low transmission with a moderate rate of SP resistance in Tanzania and the latter was carried out in an area of intense but seasonal malaria with a low rate of SP resistance in Ghana. The current IPTi study is being carried out in a site of high transmission with expected high rates of SP resistance. Data from a site 100km away indicates SP efficacy to be 55% (Mutabingwa et al, 2001). There is no data on SP or other study drugs at the ongoing study sites.
In addition there is evidence (Personal communication Chandramohan 2005) that the outcome (Adequate Parasite Response (APR)) of asymptomatic parasitaemia in infants is better than that in symptomatic 6-59 month old children when using SP. For this reason we plan a novel study examining the efficacy of SP in asymptomatic 2-10 month old infants, the target age group for IPTi.
The main objective of this component of the drug resistance study is to understand the relationship between the efficacy of antimalarial drugs used for IPTi and the long term effect of IPTi on incidence of clinical malaria. Schellenberg et al (2005). observed a 36% reduction in the incidence of clinical malaria in the second year of life in the SP IPTi group compared to the placebo group even though the last course of SP IPTi was given at 9 months of age (Schellenberg et al, 2005). This suggests that SP IPTi in an area with moderate malaria transmission and moderate levels of resistance to SP (+/-25%) IPTi may enhance the development of immunity against malaria. In contrast, a study in Ghana in area with very high and seasonal malaria transmission and very low resistance to SP (<10%) showed a 20% increase in the incidence of clinical malaria with high parasite density (>5000 parasites/ml) in SP IPTi group compared to placebo group. The nature of the relationship between drug resistance and the long term effect of IPTi on malaria remains unclear.
Parasite clearance rate depends on the efficacy of antimalarial drug and host immunity. Host immunity depends on age - immunity in infants is likely to be lower than the immunity in 1-4 year old children. Parasite clearance rate depends on parasite density, multiplicity of infection, and the type of host response - these factors differ between clinical episodes of malaria and asymptomatic parasitaemia. The interaction between antimalarial drug and host response during a clinical episode of malaria is likely to be different from that during asymptomatic malaria parasitaemia. Although infants with mild illness will not be excluded from IPTi administration at routine EPI clinics, the majority of infants will be asymptomatic when they receive IPTi. Thus results of the standard WHO in vivo drug sensitivity studies conducted in 6-59 month-old symptomatic children are unlikely to be applicable to 2-10 month old mostly asymptomatic infants receiving IPTi. However, there is no empirical evidence to support or refute this assertion.
In order to understand the relationship between level of drug resistance and long terms effects of IPTi, the exact level of drug resistance in the IPTi target infants needs to be established and related to IPTi efficacy. Thus a modified WHO in vivo drug resistance study in 2-10 month old asymptomatic infants needs to be conducted as part of the Kilimanjaro IPTi study and a comparison made with the efficacy of SP estimated from a standard WHO 6-59 month WHO in vivo efficacy study.
Objectives
We therefore propose 2 studies that have the following objectives:
- Enumerate the drug efficacies of SP and CD in the study area using the standard WHO in vivo drug efficacy methodology in symptomatic children aged 6-59 months,
- Enumerate the efficacy of SP in asymptomatic 2-10 month olds using a modified WHO in vivo drug efficacy methodology, the target population for IPTi and
- Determine the difference of efficacy when using SP for the different indications, ie between its use in symptomatic and asymptomatic children.
Methods
Study 1 is a standard in vivo WHO drug efficacy study looking at parasite positive symptomatic children between the ages of 6 and 59 months treated with SP or CD. They will be followed up after 1,2 3, 7,14,21 and 28 days. At each visit a blood slide and filter paper will be collected. Endpoints are day 28 recrudescence rates.
Study 2 is a modified in vivo drug efficacy study in the age group directly affected by IPTi, namely 2-10 months of age. Asymptomatic children will be followed up at days 1, 2, 3,7,14, 21 and 28 only. Endpoint is day 28 recrudescence rate. Blood slide and filter paper will only be taken on day 7, 14 and 28 unless the child has a fever or has reported fever in the last 48 hours.
Sample size and study subjects
Table 1 Study Arm Expected (assumed) rate of adequate parasitological response by day 28 (APR) Acceptable 95% confidence limit (precision) Sample Size needed based on expected APR and acceptable precision Total sample size (corrected for assumed 10% loss to follow-up and 10% nonadherence) 6-59 month symptomatic children SP 60% +/-6% 292* 330 CD 805 +/-7.5% 131 145
2-10 month asymptomatic children SP 75% +/-7.5% 146* 161
*SP study numbers are calculated to detect a 15% difference of APR by day 28 between symptomatic 6-59 month old children and asymptomatic 2-10 month old children with 80% power at the 5% significance level using a ratio of 2 symptomatic cases to 1 asymptomatic case.
Children attending a single health dispensary (Hale dispensary, Korogwe District,Tanga Region, Tanzania) aged between 6-59 months with a fever or history of fever within the preceding 48 hours will be asked to take part. If they fit the entry criteria (see attached protocol) and consent, they will be enrolled in the standard WHO in vivo efficacy study. Asymptomatic children aged between 2 and 10 months attending the MCH clinic for immunisations and weighing will be invited to take part in the 2-10 month efficacy study and those eligible for the study and consenting will be enrolled into the study.
Study Site
The project will take place in Hale Dispensary, a government dispensary offering primary care and MCH services to a population of more than 8,000, with an average of 30 new births a month. Hale is situated in Korogwe district,Tanga region, northeastern Tanzania and is lowland with high malaria transmission. It is less than 10 km from the IPTi study site.
Ethical considerations
It is expected that first line antimalarial drug policy will change in November 2006 from SP to lumefantrine/arthemeter. After this date it will not be ethical to continue the 6-59 month study in symptomatic children. However for the asymptomatic children it will be ethical to continue as SP use continues in asymptomatic women for IPTp and if adopted as a strategy for Tanzania, SP will be used for IPTi. Therefore we plan to carry out the SP efficacy in 6-59 month study in symptomatic children as soon as possible and if the national policy changes before completion of the study we will have to halt it. The 2-10 month old asymptomatic study will run concurrently until completion.
In the study the second line drug will be lumefantrine/arthemeter for all children should treatment fail.
Clinical safety of subjects is paramount. We will encourage mothers to bring their children for review during the follow up period when ever the child is sick. We have budgeted for a transport allowance for the mothers to help them make the journey when necessary. We will ensure 24 hour access to a member of the study team at all time. This person will be able to call on medical staff covering all clinical trial activities in Korogwe District Hospital for advice and possible emergency transfer to the hospital and assessment. An emergency vehicle is on standby 24 hours a day.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Tanga Region
-
Korogwe, Tanga Region, Tanzania
- Hale Dispensary
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For 6-59 month study
Inclusion Criteria:
- Aged 6-59 months
- Weight of 4.5 Kgs or greater.
- Not enrolled in IPTi trial
- Absence of severe malnutrition (defined as a child whose weight-for-height is below 3 standard deviations of less than 70% of the median of WHO reference values, or who has symmetrical edema involving at least the feet)
- A slide-confirmed infection with P. falciparum only
- Initial parasite density between 2,000 and 200,000 asexual parasites per microliter.
- Absence of general danger signs among children < 5 years (see below) Measured axillary temperature ³37.5 °C
- Ability to attend stipulated follow-up visits
- Informed consent provided by parent/guardian
- Absence of history of hypersensitivity reactions to any of the drugs being evaluated
Exclusion Criteria:
- Enrolled in IPTi trial
- Severe malnutrition (defined as above)
- No slide confirmed infection with P. falciparum
- Initial parasite density < 2,000 or > 200,000 asexual parasites per microliter.
- Presence of general danger signs among children < 5 years (inability to drink or breastfeed; vomiting everything; recent history of convulsions; lethargy or unconsciousness; inability to sit or stand up) or other signs of severe and complicated falciparum malaria according to WHO definitions
- Measured axillary temperature <37.5 °C
- Inability to attend stipulated follow-up visits
- Informed consent not provided by parent/guardian
- History of hypersensitivity reactions to any of the drugs being evaluated
For 2-10 month study
Inclusion criteria.
- Aged 2-10 months
- Weight of 4.5 Kgs or greater.
- Not enrolled in IPTi trial
- Absence of severe malnutrition
- A slide-confirmed infection with P. falciparum only
- Any parasite density assessed by research microscopists.
- Absence of general danger signs among children < 5 years (inability to drink or breastfeed; vomiting everything; recent history of convulsions; lethargy or unconsciousness; inability to sit or stand up) or other signs of severe and complicated falciparum malaria according to WHO definitions
- Measured axillary temperature < 37.5 °C
- Ability to attend stipulated follow-up visits
- Informed consent provided by parent/guardian
- Absence of history of hypersensitivity reactions to SP.
Exclusion criteria are not listed separately in the WHO protocol, as they are the opposite of the inclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A
SP in symptomatic children aged 6-59 months
|
Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
Other Names:
|
Experimental: B
SP to asymptomatic infected children aged 2-10 months
|
Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
Other Names:
|
Experimental: C
Chlorproguanil/dapsone in symptomatic 6-59 month old children
|
Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9
Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9
Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical /Parasitological Outcomes (WHO 2003)
Time Frame: Day 14 and 28
|
Day 14 and 28
|
Early Treatment Failure (ETF)
Time Frame: 3 days
|
3 days
|
§ Development of danger signs or severe malaria on Day 1, 2, or 3, in the presence of parasitemia
Time Frame: 3 Days
|
3 Days
|
§ Parasitemia on Day 2 higher than Day 0 count irrespective of axillary temperature
Time Frame: 2 nd day
|
2 nd day
|
§ Parasitemia on Day 3 with axillary temperature ≥37.5°C
Time Frame: 3 rd day
|
3 rd day
|
§ Parasitemia on Day 3 ≥ 25% of count on Day 0
Time Frame: 3 rd Day
|
3 rd Day
|
Late Clinical Failure (LCF)
Time Frame: After Day 3 to day 28
|
After Day 3 to day 28
|
§ Development of danger signs or severe malaria from Day 4 to Day 28 in the presence of parasitemia, without previously meeting any of the criteria of ETF
Time Frame: Day 4 - 28
|
Day 4 - 28
|
§ Presence of parasitemia and axillary temperature ≥37.5° C on any day from Day 4 to Day 28, without previously meeting any of the criteria of ETF
Time Frame: Day 4 to Day 28
|
Day 4 to Day 28
|
Late parasitological failure (LPF) -
Time Frame: Day 4 - 28
|
Day 4 - 28
|
Presence of parasitemia on Day 14, 21, or 28 and axillary temperature <37.5°C without previously meeting any of the criteria of ETF or LCF (after exclusion of re-infection by PCR for failures at days 14-28)
Time Frame: Day 14, 21, or 28
|
Day 14, 21, or 28
|
Adequate Clinical and Parasitological Response (ACPR) -
Time Frame: Day 28
|
Day 28
|
Absence of parasitemia on Day 28 irrespective of axillary temperature, without previously meeting any of the criteria of ETF, LCF or LPF
Time Frame: Day 28
|
Day 28
|
Collaborators and Investigators
Investigators
- Principal Investigator: Roly D Gosling, MD, London School of Hygiene and Tropical Medicine
- Principal Investigator: Samwel Gesase, MD, National Institute of Medical Research, Tanzania
- Principal Investigator: Jaqueline Mosha, MD, Kilimanjaro Christian Medical College, Tanzania
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Folic Acid Antagonists
- Anti-Infective Agents, Urinary
- Renal Agents
- Pyrimethamine
- Dapsone
- Chlorproguanil
- Sulfadoxine
- Fanasil, pyrimethamine drug combination
Other Study ID Numbers
- DIF 35
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on sulphadoxine/pyrimethamine
-
London School of Hygiene and Tropical MedicineMinistry of Health, GhanaCompleted
-
London School of Hygiene and Tropical MedicineMalaria Research and Training Center, Bamako, Mali; Institut de Recherche en...CompletedMalaria | Respiratory InfectionsBurkina Faso, Mali
-
University of MelbourneUniversity of Barcelona; Papua New Guinea Institute of Medical Research; The... and other collaboratorsCompletedSexually Transmitted Infections | Malaria in Pregnancy | AnaemiaPapua New Guinea
-
Papua New Guinea Institute of Medical ResearchCase Western Reserve University; University of MelbourneCompletedAnemia | MalariaPapua New Guinea
-
London School of Hygiene and Tropical MedicineCompletedTrichomonas Vaginitis | Bacterial Vaginoses | Pregnancy MalariaZambia
-
London School of Hygiene and Tropical MedicineMinistry of Health, Uganda; DBL -Institute for Health Research and DevelopmentCompletedAnemia | Pregnancy | MalariaUganda
-
University College Hospital, IbadanUnknown
-
Ghana Health ServicesNetherlands Overseas AgencyCompleted
-
London School of Hygiene and Tropical MedicineKintampo Health Research Centre, GhanaNot yet recruitingMalaria | Schistosomiasis | Soil Transmitted Helminths | Seasonal Malaria Chemoprevention | Mass Drug Administration With Anthelminthic Drugs
-
London School of Hygiene and Tropical MedicineUniversity of Copenhagen; National Institute for Medical Research, Tanzania; Kilimanjaro...Completed